

Clinical trials of olmesartan

TrialResults-center www.trialresultscenter.org

1 hypertension

| Trial | Treatments | Patients | Trials design and methods |
|--|---|---|---------------------------|
| olmesartan 40 mg vs olmesartan 20 mg plus a calcium-channel blocker | | | |
| OSCAR , 2011 [NCT00134160] n=578/586 follow-up: | high-dose olmesartan 40 mg per day versus 20-mg/day olmesartan comined with standard dose of amlodipine or azelnidipine | high-risk elderly Japanese hypertension patients | Parallel groups Japan |

More details and results :

- anti hypertensive agents for hypertension in all type of patient at <http://www.trialresultscenter.org/go-Q13>
- angiotensin-receptor blockers for hypertension in all diseases requiring ACEi (HF, CHD, HT,...) at <http://www.trialresultscenter.org/go-Q125>
- anti hypertensive agents for hypertension in patients with additional risk factor at <http://www.trialresultscenter.org/go-Q686>

References

OSCAR, 2011:

Ogawa H, Kim-Mitsuyama S, Jinnouchi T, Matsui K, Arakawa K Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160). Hypertens Res 2009;32:575-80 [[19444280](https://pubmed.ncbi.nlm.nih.gov/19444280/)] [10.1038/hr.2009.60](https://doi.org/10.1038/hr.2009.60)

2 miscellaneous

| Trial | Treatments | Patients | Trials design and methods |
|------------------------------|------------|----------|---------------------------|
| olmesartan vs placebo | | | |

continued...

| Trial | Treatments | Patients | Trials design and methods |
|--|---|---|--|
| ROADMAP , 2010 [NCT00185159] n=2232/2215 follow-up: 3.2 y | olmesartan at 40 mg/day versus placebo | patients with diabetes and at least one additional cardiovascular risk factor, but no evidence of renal dysfunction | Parallel groups double-blind Europe (19 countries) |
| ORIENT [NCT00141453] n=282/284 follow-up: | olmesartan versus placebo | patients with diabetic Nephropathy and overt proteinuria secondary to type 2 diabetes mellitus | Parallel groups double-blind Japan, Hong Kong |
| olmesartan 40 mg vs olmesartan 20 mg plus a calcium-channel blocker | | | |
| OSCAR , 2011 [NCT00134160] n=578/586 follow-up: | high-dose olmesartan 40 mg per day versus 20-mg/day olmesartan comined with standard dose of amlodipine or azelnidipine | high-risk elderly Japanese hypertension patients | Parallel groups Japan |

More details and results :

- angiotensin-receptor blockers for miscellaneous in all type of patients at <http://www.trialresultscenter.org/go-Q425>

2

References

ROADMAP, 2010:

Ritz E, Viberti GC, Ruilope LM, Rabelink AJ, Izzo JL Jr, Katayama S, Ito S, Mimran A, Menne J, Rump LC, Januszewicz A, Haller H Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. *Diabetologia* 2010;53:49-57 [19876613] [10.1007/s00125-009-1577-3](https://doi.org/10.1007/s00125-009-1577-3)

Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. *N Engl J Med* 2011 Mar 10;364:907-17 [21388309]

ORIENT, :

OSCAR, 2011:

Ogawa H, Kim-Mitsuyama S, Jinnouchi T, Matsui K, Arakawa K Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160). *Hypertens Res* 2009;32:575-80 [19444280] [10.1038/hr.2009.60](https://doi.org/10.1038/hr.2009.60)

3 atrial fibrillation

| Trial | Treatments | Patients | Trials design and methods |
|---|--|---|--|
| olmesartan vs placebo | | | |
| ANTIPAF <i>ongoing</i> [NCT00098137] n=214/211 follow-up: 12 months | olmesartan 40mg daily versus placebo | patients with paroxysmal atrial fibrillation | Parallel groups double blind germany |

More details and results :

- prevention for atrial fibrillation in patient with history of atrial fibrillation at <http://www.trialresultscenter.org/go-Q328>

References

ANTIPAF, :

ongoing trial NCT00098137

4 diabetes type 2

3

| Trial | Treatments | Patients | Trials design and methods |
|---|--|---|--|
| olmesartan vs placebo | | | |
| ROADMAP , 2010 [NCT00185159] n=2232/2215 follow-up: 3.2 y | olmesartan at 40 mg/day versus placebo | patients with diabetes and at least one additional cardiovascular risk factor, but no evidence of renal dysfunction | Parallel groups double-blind Europe (19 countries) |
| ORIENT [NCT00141453] n=282/284 follow-up: | olmesartan versus placebo | patients with diabetic Nephropathy and overt proteinuria secondary to type 2 diabetes mellitus | Parallel groups double-blind Japan, Hong Kong |

More details and results :

- anti hypertensive agents for diabetes type 2 in patients with or without hypertension at <http://www.trialresultscenter.org/go-Q414>
- angiotensin-receptor blockers for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q427>
- angiotensin renin system blockade for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q438>

References

ROADMAP, 2010:

Ritz E, Viberti GC, Ruilope LM, Rabelink AJ, Izzo JL Jr, Katayama S, Ito S, Mimran A, Menne J, Rump LC, Januszewicz A, Haller H Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Diabetologia 2010;53:49-57 [19876613] [10.1007/s00125-009-1577-3](https://doi.org/10.1007/s00125-009-1577-3)

Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011 Mar 10;364:907-17 [21388309]

ORIENT, :

5 diabetic kidney disease

| Trial | Treatments | Patients | Trials design and methods |
|---|---------------------------------|--|---|
| olmesartan vs placebo | | | |
| ORIENT [NCT00141453] n=282/284 follow-up: | olmesartan versus placebo | patients with diabetic Nephropathy and overt proteinuria secondary to type 2 diabetes mellitus | Parallel groups double-blind Japan, Hong Kong |

More details and results :

- All mechanism for diabetic kidney disease in all type of patients at <http://www.trialresultscenter.org/go-Q667>

References

ORIENT, :

Entry terms: olmesartan medoxomil, CS 866, CS-866, Votum, Benicar, Olmetec,